



BRAWN



3EB5A

CIN NO.: L74899DL1985PLC022468

14th February, 2023

**The General Manager
The Department of Corporate Services,
BSE Limited, 25th Floor,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai -400001**

**BSE Scrip Code: 530207
Scrip ID: BRAWN**

Sub: Outcome of Board Meeting and Submission of unaudited Financial Results for the quarter 31.12.2022.

Dear Sir/ Ma'am,

We wish to inform you that pursuant to the Regulation 30 and 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 and any other applicable provisions, if any, the Board of Directors of the Company, at its meeting held on today i.e. 14th February, 2023, inter-alia considered and approved/noted the Standalone Un-audited Financial Results along with Limited Review Report by the Company's Statutory Auditor for the quarter ended 31st December, 2022, a copy of which is enclosed herewith.

We wish to further inform you that the meeting of the Board of directors commenced at 03:00 PM and concluded at 03:30 PM.

This is for your kind information and record.

Thanking You.

**For and on behalf of
BRAWN BIOTECH LIMITED**

**Priyanka Sharma
Company Secretary & Compliance Officer**




Encl: As above

BRAWN BIOTECH LTD.
(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana, INDIA Tel: 0124-4666152, 4222462
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

...for better life

**BRAWN**

3E41C

CIN NO.: L74899DL1985PLC022468

BRAWN BIOTECH LIMITED						
CIN:L74899DL1985PLC022468						
REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024						
STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER 2022						
Sr.	Particulars	Quarter ended		Nine Months ended		Rs in Lacs
		31.12.2022	30.09.2022	31.12.2021	31.12.2021	Year Ended
		Un-audited	Un-audited	Un-audited	Un-audited	31.03.2022
1	Revenue from operations					Audited
	Revenue from operations	630.89	776.70	252.78	1,747.80	862.05
	Other income	0.23	0.30	-	0.55	0.37
	Total Revenue	631.13	777.00	252.78	1,748.35	862.42
2	Expenses					
a	Cost of material consumed	2.31	5.44	-	7.75	-
b	Purchase of stock-in-trade	638.43	771.29	422.47	1,601.62	1,105.35
c	Change in inventories of finished goods, work in progress and stock in trade	-88.08	-44.87	-133.87	-83.65	-446.68
d	Employee Benefit expenses	32.56	33.60	31.91	101.71	180.44
e	Depreciation and amortisation expenses	2.61	2.45	1.58	7.37	5.33
f	Finance Cost	0.03	0.39	0.15	0.45	6.25
g	Other expenses	46.99	44.94	87.35	137.67	223.51
	Total Expenses	634.85	813.22	409.51	1,772.91	1,074.20
	Profit from Operation before Other Income, exceptional and extra-ordinary items					
3	(1-2)	-3.72	-36.22	-156.73	-24.56	-211.78
4	Other income	-	-	-	-	-
5	Profit from ordinary activities before exceptional items (3-4)	-3.72	-36.22	-156.73	-24.56	-211.78
6	Exceptional items	-	-	-	-	-
7	Profit from ordinary activities before tax (5-6)	-3.72	-36.22	-156.73	-24.56	-211.78
8	Tax Expenses	-	-0.80	-	1.46	-47.34
9	Profit (Loss) for the period from continuing operations (7-8)	-3.72	-35.42	-156.73	-26.02	-164.44
10	Profit/(loss) from discontinuing operations	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-
13	Profit (Loss) for the period (9+12)	-3.72	-35.42	-156.73	-26.02	-164.44
14	Other Comprehensive Income	(1.77)	(1.98)	(2.08)	(4.06)	8.96
	Total Comprehensive Income	-5.49	-37.40	-158.81	-30.08	-157.48
15	Details of equity share capital	300.03	300.03	300.03	300.03	300.03
	Paid-up equity share capital	-	-	-	-	-
	Face Value of equity share capital	-	-	-	-	-
16	Reserve excluding Revaluation Reserve	-	-	-	-	-
17	Earnings per share					
I	Basic earnings per share	(0.18)	(1.25)	(5.29)	(1.00)	(5.25)
II	Diluted earnings per share	(0.18)	(1.25)	(5.29)	(1.00)	(5.25)

NOTES -

1 Results for the quarter ended on 31st December, 2022 were reviewed by the Audit committee and then approve by the Board of Directors at their meeting held on 14 February, 2023.

The Statutory Auditors carried out the limited review for quarter ended 31st December, 2022. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.

The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment) rules, 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

4 The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.

5 The above Standalone Un-audited Financial Results for the quarter ended on 31-12-2022 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.

6 Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board

For Brawn Biotech Limited

Dr. Raj Gupta

Director

DIN NO. 00974949

Date: 14.02.2023

Place: Delhi



BRAWN BIOTECH LTD.
(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana, INDIA Tel: 0124-4666152, 4222462
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

...for better life



To,
The Board of Directors of
Brawn Biotech Limited

We have reviewed the accompanying statement of unaudited financial results of **Brawn Biotech Limited** for the period ended 31st December 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 018764N

Rajeev Jain

Rajeev Jain
Partner

Membership No. 099767
UDIN: 23099767BGSJGT3296



Place: Delhi
Date: 14-02-2023